Objectives

Breaking down barriers

Our activities and our collaboration with our partners is led by our overarching commitment in promoting health innovation and R&D to achieve our SDG targets by 2030 and beyond. While promoting awareness raising amongst policymakers and suggesting solutions, initiatives in tackling some of the world’s deadliest diseases such as malaria, tuberculosis, HIV and AIDS, sepsis and cardiovascular diseases and neglected tropical diseases, we focus on overarching challenges to drive system changes that can help to tackle these diseases in and between countries. We provide concrete solutions that help eradicate and tackle some of the world’s deadliest diseases.

Unlike traditional health advocacy groups our recommendations to the G20 and also the G7, our activities and our thought leadership is guided by a macro-economic lens on the overall global health advancement and health systems strengthening agenda. Our common mission and vision promote the risk-return-impact narrative in global health advancement guided by the UN SDG 2030 targets.

The global COVID-19 pandemic has highlighted that current and future health challenges do not respect borders. As the current pandemic will cost our economies and societies around 22 trillion USD by 2025 as estimated by the G20 High-Level Panel of Financing the Common Goods, our objective is to look at outcome-oriented scenarios with our partners and prevent any future disaster.

Our vision helps us promote solutions today

SDG 3
SDG 17

Objectives

Recommendations

G20HDP slider 24

+

Placing health at the centre

Placing health at the centre of sustainable economic development, and recognising that economic development alone is not a guarantee that health inequalities will be decreased.

G20HDP slider 15

+

Sensibly applied technology

Scoping the health technology horizon for gaps that need to be filled in order to lessen inequalities in health and to fulfil SDG 3 commitments.

+

Identifying sustainable finance

Recognizing the importance of actively promoting existing and innovative financing models for global health research (R&D), together with upscaling successful partnerships and delivery mechanisms during the G20 presidency, with the engagement of those who benefitted most from globalisation.

G20HDP slider 49

+

Inclusive partnership models

Including foundations, philanthropies and businesses/the pharmaceutical industry together with product development partnerships (PDPs) that all have shared-values as actors in the G20 health dialogue and decision-making process.

G20HDP Globe

+

Global government support model

Continuing to engage with governments globally to promote the health of their populations using a mix of traditional, national and international funding together with resources generated by new innovations in health financing.

G20HDP slider 14

+

Expert collaboration for innovation

Creating a high-level panel following the G20 Joint Session of Health and Finance Ministers, in collaboration with the OECD and the World Bank to fully implement these recommendations, with the intention of establishing new long-term ways of funding innovation in health.